Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Pastimes : Clown-Free Zone... sorry, no clowns allowed -- Ignore unavailable to you. Want to Upgrade?

To: Ilaine who wrote (62117)	1/26/2001 2:29:14 PM
From: LLCF	Read Replies (2) \| Respond to of 436258

<DAK, I understand your point, but from an epidemiological point of view, the way these things are studied is to eliminate the co-variables you mention, and try to drill down in the data to the variable being studied.> That is not the case here. All patients are assumed to be taking the medications for a reason no? It says nowhere in the study that it was done on a symptomless population unless I missed something. It would be interesting to know how many of that population had severe pain, no? <NSAIDS cause gastropathy because they inhibit COX-2, which causes pain and inflammation, and COX-1, which has a beneficial effect on the gastric mucosa. That's why Celebrex and Vioxx are such blockbuster drugs, they are selective COX-2 inhibitors.*> Yes, enzyme inhibition is popular in western medicine... ie. try to cover or rebalance rather than treating the root cause. DAK